Literature DB >> 29567579

Palliative shunt surgery for patients with leptomeningeal metastasis.

Yuta Murakami1, Masahiro Ichikawa2, Mudathir Bakhit3, Shinya Jinguji4, Taku Sato5, Masazumi Fujii6, Jun Sakuma7, Kiyoshi Saito8.   

Abstract

OBJECTIVES: Leptomeningeal metastasis (LM) is associated with poor prognosis and affects the quality of life (QOL) of end-stage cancer patients. Severe headache associated with hydrocephalus causes reduced QOL. We investigated the clinical value of surgical treatment for hydrocephalus in LM patients. PATIENTS AND METHODS: The medical records of 11 consecutive patients who underwent lumboperitoneal shunt (LPS) or ventriculoperitoneal shunt (VPS) at our institution between 2007 and 2016 were investigated. Primary brain tumor patients were excluded. We assessed the neurological status and therapeutic effects at 1 month after the shunt surgery.
RESULTS: The patients were three males and eight females with a median age of 58 years (interquartile range [IR] 52-68 years). The median preoperative neutrophil-to-lymphocyte ratio was 6.4 (IR 4.8-9.2). Symptom improvement was observed in nine patients, and severe headache was relieved in seven (88%) out of eight patients. The median Karnofsky performance status scale increased from 40 to 60, and the median overall survival after primary malignancy diagnosis was 27.4 months (IR 19.6-63.1 months). The median survival after the diagnosis of brain parenchymal metastasis, LM, and shunt surgery were 7.2 months (IR 5.1-14.1 months), 3.9 months (IR 3.5-6.3 months), and 3.3 months (IR 2.9-5.7 months), respectively.
CONCLUSION: Shunt surgery for hydrocephalus could offer an effective palliative surgical option for symptom relief especially relief of severe headache, contributing improvement of QOL in LM patients.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hydrocephalus; Leptomeningeal metastasis; Neutrophil-to-lymphocyte ratio; Palliative surgery; Shunt surgery

Mesh:

Year:  2018        PMID: 29567579     DOI: 10.1016/j.clineuro.2018.03.008

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  6 in total

1.  Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes.

Authors:  Evan D Bander; Melissa Yuan; Anne S Reiner; Andrew L A Garton; Katherine S Panageas; Cameron W Brennan; Viviane Tabar; Nelson S Moss
Journal:  J Neurooncol       Date:  2021-08-18       Impact factor: 4.506

2.  Cerebrospinal fluid diversion and outcomes for lung cancer patients with leptomeningeal carcinomatosis.

Authors:  Yan-Hua Su; Chi-Lu Chiang; Huai-Che Yang; Yong-Sin Hu; Yu-Wei Chen; Yung-Hung Luo; Ching-Jen Chen; Hsiu-Mei Wu; Chung-Jung Lin; Cheng-Chia Lee
Journal:  Acta Neurochir (Wien)       Date:  2021-03-01       Impact factor: 2.216

Review 3.  Leptomeningeal metastases: the future is now.

Authors:  Rimas V Lukas; Jigisha P Thakkar; Massimo Cristofanilli; Sunandana Chandra; Jeffrey A Sosman; Jyoti D Patel; Priya Kumthekar; Roger Stupp; Maciej S Lesniak
Journal:  J Neurooncol       Date:  2022-01-20       Impact factor: 4.130

Review 4.  Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma.

Authors:  Yolanda Piña; Sirisha Yadugiri; Debra N Yeboa; Sherise D Ferguson; Peter A Forsyth; Isabella C Glitza Oliva
Journal:  Curr Oncol Rep       Date:  2022-01-20       Impact factor: 5.075

Review 5.  Management of hydrocephalus in patients with leptomeningeal metastases: an ethical approach to decision-making.

Authors:  Nayan Lamba; Tim Fick; Rhishi Nandoe Tewarie; Marike L Broekman
Journal:  J Neurooncol       Date:  2018-07-18       Impact factor: 4.130

6.  Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study.

Authors:  Junjie Zhen; Lei Wen; Mingyao Lai; Zhaoming Zhou; Changguo Shan; Shaoqun Li; Tao Lin; Jie Wu; Wensheng Wang; Shaoqiang Xu; Da Liu; Ming Lu; Dan Zhu; Longhua Chen; Linbo Cai; Cheng Zhou
Journal:  Radiat Oncol       Date:  2020-07-31       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.